S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Study Chair - Halle C Moore, MD
The Cleveland Clinic
Principal Investigator - Kathy S. Albain, MD
Loyola University
Study Chair - Kelly-Anne Phillips
Peter MacCallum Cancer Centre, Australia
Study Chair - Lori J. Goldstein, MD
Fox Chase Cancer Center
Study Chair - Silvana Martino, DO
Saint John's Cancer Institute
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mater Hospital - North Sydney
North Sydney, New South Wales, Australia
- Royal North Shore Hospital
St Leonards, New South Wales, Australia
- Newcastle Mater Misericordiae Hospital
Waratah, New South Wales, Australia
- Royal Adelaide Hospital Cancer Centre
Adelaide, South Australia, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Royal Hobart Hospital
Hobart, Tasmania, Australia
- Ballarat Oncology and Haematology Services
Ballarat, Victoria, Australia
- Box Hill Hospital
Box Hill, Victoria, Australia
- Monash Medical Center - Clayton Campus
Clayton, Victoria, Australia
- Peter Maccallum Cancer Centre
East Melbourne, Victoria, Australia
- Maroondah Hospital
East Ringwood, Victoria, Australia
- St. Vincent'S Hospital - Melbourne
Fitzroy, Victoria, Australia
- Royal Melbourne Hospital
Parkville, Victoria, Australia
- Royal Perth Hospital
Perth, Western Australia, Australia
- Centre Hospitalier Hutois
Huy, Belgium
- U.Z. Gasthuisberg
Leuven, Belgium
- Chu Liege - Domaine Universitaire Du Sart Tilman
Liège, Belgium
- Centre Hospitalier Regional de la Citadelle
Liège, Belgium
- Az Damiaan
Ostend, Belgium
- Centre Hospitalier Peltzer-la Tourelle
Verviers, Belgium
- National Institute of Oncology
Budapest, Hungary
- Ospedali Riuniti Di Bergamo
Bergamo, Italy
- Ospedale Degli Infermi - Asl 12
Biella, Italy
- Ospedale Civile Ramazzini
Carpi, Italy
- Ospedale Alessandro Manzoni
Lecco, Italy
- European Institute of Oncology
Milan, Italy
- Auckland City Hospital
Auckland, New Zealand
- Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
- Inselspital Bern
Bern, Switzerland
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
- Oncology Institute of Southern Switzerland - Locarno
Locarno, Switzerland
- Oncology Institute of Southern Switzerland - Lugano
Lugano, Switzerland
- Oncology Institute of Southern Switzerland - Mendrisio
Mendrisio, Switzerland
- Regionalspital
Thun, Switzerland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2003
- Primary completion
- 31 Jan 2014
- Completion
- 30 Sept 2016
- Last update posted
- 30 Dec 2019
- Registered enrollment
- 257
- Registry id
- NCT00068601
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.